Results 21 to 30 of about 852 (150)

A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab

CPT: Pharmacometrics & Systems Pharmacology, 2021
A model to quantitatively characterize the effect of evinacumab, an investigational monoclonal antibody against angiopoietin‐like protein 3 (ANGPTL3) on lipid trafficking is needed.
Masood Khaksar Toroghi, Jim Bosley, Lyn M. Powell, Yi Zhang, Feng Yang, Xia Pu, John D. Davis, Nidal Al‐Huniti   +7 more
doaj   +1 more source

THE IMPACT OF EVINACUMAB THERAPY ON PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM PART B OF A PHASE 3 TRIAL

American Journal of Preventive Cardiology, 2023
Therapeutic Area: ASCVD /CVD Risk Reduction Background: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels.
Albert Wiegman, Susanne Greber-Platzer, Shazia Ali, Divya Singh, M. Doortje Reijman, Eliot A Brinton, Min-Ji Charng, Shubha Srinivasan, Carissa Baker-Smith, Seth Baum, Julie Brothers, Jacob Hartz, Patrick M. Moriarty, Poulabi Banerjee, Richard T George, Robert Pordy   +15 more
doaj   +1 more source

Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia

Cardiology Journal, 2023
Angiopoietin-like proteins (ANGPTL) are involved in the regulation of numerous physiological and biochemical processes. ANGPTL3, 4 and 8, which are involved in the regulation of lipoprotein metabolism, are particularly important.
Stanisław Surma, Monika Romańczyk, Krzysztof J. Filipiak   +2 more
doaj   +1 more source

Evinacumab for children with homozygous familial hypercholesterolemia: a plain language summary. [PDF]

Future Cardiol
What is this summary about? This is a plain language summary explaining the results of a study assessing a treatment, called evinacumab, for children with a condition called homozygous familial hypercholesterolemia, also known as HoFH. HoFH is a rare genetic disorder that makes the liver less able to remove ‘bad’cholesterol (called low-density ...
Wiegman A, Pordy R.
europepmc   +4 more sources

Correction to: Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia. [PDF]

Circulation
Wiegman A, Greber-Platzer S, Ali S, Doortje Reijman M, Brinton EA, Charng MJ, Srinivasan S, Baker-Smith C, Baum S, Brothers JA, Hartz J, Moriarty PM, Mendell J, Bihorel S, Banerjee P, George RT, Hirshberg B, Pordy R.   +17 more
europepmc   +4 more sources

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins [PDF]

Diabetes & Metabolism Journal, 2022
Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, even under optimal statin therapy, a significant residual ASCVD risk remains.
Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi   +2 more
doaj   +1 more source

Evinacumab Improved the Homozygous Familial Hypercholesterolemia Lipid Metabolism: A Case Report. [PDF]

J Atheroscler Thromb
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by high levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of early onset atherosclerosis. Evinacumab, an angiopoietin-like protein 3 (ANGPTL3)-inhibiting monoclonal antibody, lowers LDL-C independently of LDL receptor activity.
Matsuda T, Osaki Y, Matsumoto N, Nakajima R, Murayama Y, Sugano Y, Iwasaki H, Mathis BJ, Sekiya M, Shimano H.   +9 more
europepmc   +3 more sources

New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)

Journal of Lipid and Atherosclerosis, 2023
Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). There are abundant and unequivocal data to indicate that low-density lipoproteins (LDL) are a cause of ASCVD.
Kyung An Kim, Hun-Jun Park
doaj   +1 more source

Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice[S]

Journal of Lipid Research, 2020
Atherosclerosis-related CVD causes nearly 20 million deaths annually. Most patients are treated after plaques develop, so therapies must regress existing lesions. Current therapies reduce plaque volume, but targeting all apoB-containing lipoproteins with
Marianne G. Pouwer, Elsbet J. Pieterman, Nicole Worms, Nanda Keijzer, J. Wouter Jukema, Jesper Gromada, Viktoria Gusarova, Hans M.G. Princen   +7 more
doaj   +1 more source

Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia

JAMA Cardiology, 2023
ImportancePatients with refractory hypercholesterolemia who do not achieve their guideline-defined low-density lipoprotein cholesterol (LDL-C) thresholds despite treatment with maximally tolerated combinations of lipid-lowering therapies (LLTs) have an increased risk of atherosclerotic cardiovascular disease (ASCVD).ObjectiveTo evaluate longer-term ...
Rosenson, Robert S., Burgess, Lesley J., Ebenbichler, Christoph F., Baum, Seth J., Stroes, Erik S. G., Ali, Shazia, Khilla, Nagwa, McGinniss, Jennifer, Gaudet, Daniel, Pordy, Robert   +9 more
openaire   +2 more sources